newsfilter
← Latest News
GlobeNewswire·

Cassava Reports Q3 2025 Financials Results and Provides Business Update

Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board